NP
TMO icon

Ninepoint Partners’s Thermo Fisher Scientific TMO Stock Holding History

Ninepoint Partners’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-878
Closed -$432K – 185
2026
Q1 		$432K Hold
878
– – 0.03% 119
2025
Q4 		$509K Buy
878
+355
+68% +$201K 0.06% 114
2025
Q3 		$254K Buy
+523
New +$243K 0.03% 108
2024
Q4 		– Sell
-1,154
Closed -$714K – 98
2024
Q3 		$714K Sell
1,154
-45
-4% -$26.6K 0.08% 76
2024
Q2 		$663K Sell
1,199
-128
-10% -$73.3K 0.06% 76
2024
Q1 		$771K Hold
1,327
– – 0.08% 63
2023
Q4 		$704K Buy
1,327
+117
+10% +$56.6K 0.08% 55
2023
Q3 		$612K Hold
1,210
– – 0.06% 58
2023
Q2 		$631K Buy
1,210
+143
+13% +$77.2K 0.07% 59
2023
Q1 		$615K Buy
1,067
+278
+35% +$157K 0.07% 51
2022
Q4 		$434K Buy
+789
New +$418K 0.06% 55
2022
Q1 		– Sell
-802
Closed -$535K – 102
2021
Q4 		$535K Buy
+802
New +$501K 0.16% 40
2021
Q2 		– Sell
-1,020
Closed -$466K – 95
2021
Q1 		$466K Buy
1,020
+229
+29% +$109K 0.19% 43
2020
Q4 		$368K Sell
791
-282
-26% -$132K 0.14% 55
2020
Q3 		$474K Hold
1,073
– – 0.21% 17
2020
Q2 		$389K Sell
1,073
-230
-18% -$77.1K 0.16% 33
2020
Q1 		$370K Sell
1,303
-306
-19% -$96.5K 0.37% 27
2019
Q4 		$523K Hold
1,609
– – 0.17% 35
2019
Q3 		$469K Sell
1,609
-556
-26% -$159K 0.18% 58
2019
Q2 		$636K Sell
2,165
-1,640
-43% -$452K 0.12% 51
2019
Q1 		$1.04M Hold
3,805
– – 0.19% 45
2018
Q4 		$852K Sell
3,805
-295
-7% -$69.2K 0.23% 33
2018
Q3 		$1M Hold
4,100
– – 0.17% 47
2018
Q2 		$849K Buy
4,100
+1,400
+52% +$297K 0.09% 51
2018
Q1 		$557K Buy
2,700
+1,200
+80% +$252K 0.04% 68
2017
Q4 		$285K Buy
+1,500
New +$287K 0.02% 111

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ninepoint Partners's TMO Position: Q2 2026 in Review

Ninepoint Partners sold out of Thermo Fisher Scientific (TMO) in Q2 2026, closing a stake of 878 shares — an estimated $432K sold.

Ninepoint Partners first reported a position in TMO in Q4 2017 and held it in 26 quarters. The position peaked at $1.04M in Q1 2019. 2,620 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Ninepoint Partners reported no remaining Thermo Fisher Scientific position as of Q2 2026 after selling out during the quarter.
  • Ninepoint Partners sold 878 Thermo Fisher Scientific shares in Q2 2026, an estimated $432K.
  • Ninepoint Partners first reported a position in Thermo Fisher Scientific in Q4 2017 and held it in 26 quarters.
  • Ninepoint Partners's Thermo Fisher Scientific position peaked at $1.04M in Q1 2019.
  • 2,620 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Ninepoint Partners's 13F filing for Q2 2026, filed 11 Aug 2026.